This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
LIFE was a randomized, parallel, double-masked phase 3 trial with a primary purpose of prevention. The study evaluated MK0954, identified as losartan in the trial title, against atenolol in the setting of hypertension and left ventricular hypertrophy.
| Feature | LIFE |
|---|---|
| Trial acronym | LIFE |
| Study title | Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) |
| Phase | Phase 3 |
| Status | Completed |
| Condition | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Primary purpose | Prevention |
| Enrollment | 496 |
| Lead sponsor | Organon and Co |
| Sponsor type | Industry |
| ClinicalTrials.gov | NCT00338260 |
2. Clinical Question
The central clinical-trial question concerns whether the study treatment, MK0954 identified as losartan in the study title, should be compared with atenolol with respect to a composite of major cardiovascular events in the population with hypertension and left ventricular hypertrophy.
Population
People with hypertension and left ventricular hypertrophy, described in the registry as thickening of the main pumping chamber of the heart.
Intervention
MK0954, identified as losartan in the study title, with a listed duration of treatment of 5 years.
Comparator
Atenolol, with a listed duration of treatment of 5 years.
Primary question
How does the randomized comparison of MK0954 versus atenolol relate to the prespecified composite cardiovascular endpoint?
3. Trial Design
The registry describes LIFE as a phase 3, randomized, parallel, double-masked study with a primary purpose of prevention. The total enrollment was 496 participants. Both listed interventions had a treatment duration of 5 years.
MK0954
- Study intervention identified as MK0954
- The trial title identifies the intervention as losartan
- Listed duration of treatment: 5 years
Atenolol
- Comparator intervention: atenolol
- Listed duration of treatment: 5 years
4. Trial Timeline
Study start
The registry lists June 1995 as the study start date.
Primary completion
The registry lists September 2001 as the primary completion date.
Registry status
The ClinicalTrials.gov record identifies the study status as completed.
5. Primary Endpoint
The registry lists one registered primary endpoint. It is a composite cardiovascular endpoint consisting of several clinically distinct event types.
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Primary endpoint | Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack) | The registry information provided does not specify a separate endpoint time frame. |
What the composite endpoint combines
Cardiovascular death · fatal and nonfatal stroke · fatal and nonfatal myocardial infarction
Composite endpoints are useful when a trial is designed around several clinically important events rather than a single outcome. Statistically, however, the individual components are not interchangeable. A composite result reflects the combined occurrence of the prespecified components, so interpretation should consider what types of events contribute most strongly to the observed endpoint.
6. Understanding the Composite Endpoint
Why combine cardiovascular death, stroke, and myocardial infarction?
A composite endpoint can increase the number of observed events relative to any single component, which can make a randomized comparison more statistically informative when the components are sufficiently related to the clinical question. The trade-off is interpretational: the composite does not provide a single description of one biological event. It represents the first or otherwise qualifying occurrence among the component events under the endpoint definition.
Cardiovascular death
This is one component of the registered composite and represents a fatal cardiovascular outcome.
Stroke
The endpoint explicitly includes both fatal and nonfatal stroke.
Myocardial infarction
The endpoint explicitly includes both fatal and nonfatal myocardial infarction, or heart attack.
Composite interpretation
The overall endpoint combines these event categories rather than treating them as separate primary endpoints.
For a time-to-event composite, the statistical estimand is usually based on the time until the first qualifying component event. That approach prevents a single participant from contributing multiple first-event failures to the same primary analysis, while preserving the distinction among the component outcomes for clinical interpretation.
7. Planned Analysis
For a randomized trial with a composite cardiovascular endpoint of this type, a conventional primary analysis would typically treat the endpoint as a time-to-event outcome. The analysis would compare the time from randomization to the first qualifying cardiovascular death, fatal or nonfatal stroke, or fatal or nonfatal myocardial infarction.
The survival function S(t) represents the probability of remaining free of the defined event through time t. In a clinical trial, Kaplan-Meier estimation is commonly used to estimate this function when follow-up times differ across participants.
Kaplan-Meier estimation
A Kaplan-Meier analysis would estimate the probability of remaining free of the composite endpoint over follow-up. Participants who have not experienced the endpoint by their last available observation can contribute information up to the point at which they are censored.
Log-rank comparison
A log-rank test is commonly used to compare the time-to-event distributions between randomized treatment groups. Its null hypothesis concerns the equality of the underlying event-time distributions, subject to the assumptions of the test and censoring framework.
Cox proportional-hazards model
A Cox proportional-hazards model is commonly used to estimate a hazard ratio for the treatment comparison. In its basic form, the hazard ratio summarizes the relative instantaneous event rate between treatment groups under the proportional-hazards assumption.
The coefficient associated with treatment, when exponentiated, gives a hazard ratio. A hazard ratio below 1 would correspond to a lower estimated instantaneous event rate in the treatment group; a value above 1 would correspond to a higher estimated instantaneous event rate.
The registry information available here does not report a prespecified log-rank test, Cox model, stratification scheme, alpha-spending method, multiplicity procedure, missing-data strategy, or analysis population definition. Those details therefore cannot be attributed to the LIFE registry record.
8. Statistical Methods Explained
Why is a time-to-event analysis appropriate for this endpoint?
The registered endpoint describes major cardiovascular events that can occur at different times during follow-up. A time-to-event framework preserves information about when an event occurs and can accommodate participants whose follow-up ends before an event is observed through censoring.
What would a hazard ratio represent?
A hazard ratio would compare the estimated instantaneous rate of experiencing the composite endpoint between the randomized groups over the analyzed follow-up. It would not be equivalent to a simple percentage difference in the number of participants experiencing an event.
Why does the composite need component-level interpretation?
Cardiovascular death, stroke, and myocardial infarction have different clinical characteristics. Even if they are analyzed together as one primary endpoint, the meaning of the composite depends partly on how the individual components contribute to the overall event count.
What does censoring mean?
Censoring occurs when a participant's event-free follow-up ends before the composite endpoint is observed. In a Kaplan-Meier or Cox analysis, that participant can contribute information up to the censoring time without being treated as though an endpoint event occurred at that time.
Why does proportional hazards matter for a Cox model?
The conventional Cox proportional-hazards interpretation assumes that the relative hazard between treatment groups is reasonably stable over time. If the treatment effect changes substantially with time, a single hazard ratio may provide an incomplete description of the treatment difference, and other time-dependent summaries may be informative.
Why is the primary endpoint a composite rather than three separate primary endpoints?
The registry explicitly defines the primary endpoint as a composite. Statistically, this creates one primary outcome definition containing cardiovascular death, fatal and nonfatal stroke, and fatal and nonfatal myocardial infarction. The resulting analysis therefore concerns the composite as defined rather than treating each component as an independent primary hypothesis.
9. Randomization and Causal Interpretation
The randomized allocation is an important feature of the LIFE design. Randomization is intended to make the treatment groups comparable, on average, with respect to both measured and unmeasured characteristics at baseline. This provides the foundation for attributing differences in subsequent outcomes to treatment assignment rather than to systematic baseline selection.
Randomization does not guarantee that every baseline characteristic will be numerically identical between groups. Its statistical value comes from establishing a randomized treatment-assignment mechanism before outcomes are observed. The resulting comparison can then be interpreted as a comparison of outcomes associated with the assigned interventions under the trial protocol.
10. Analysis Population Considerations
The registry information identifies the study as randomized and provides an enrollment of 496, but it does not specify an intention-to-treat definition, per-protocol population, safety population, or other formal analysis-population definitions.
| Population concept | Statistical role |
|---|---|
| Randomized population | Provides the natural foundation for an intention-to-treat efficacy comparison. |
| Intention-to-treat population | Typically preserves randomized treatment assignment for the primary efficacy comparison. |
| Per-protocol population | Can describe outcomes among participants sufficiently adherent to protocol-defined treatment and follow-up, but may be subject to post-randomization selection. |
| Safety population | Typically defined using actual treatment exposure when assessing adverse events. |
For the LIFE record, the specific definitions of these populations are not reported in the information available from the registry record.
11. Composite Endpoint: Statistical Interpretation
If a hazard ratio were reported for the composite endpoint, it would quantify the relative rate of the first qualifying composite event between randomized groups under the specified survival model. It would not identify the relative effect on every component of the composite individually.
A 95% confidence interval around a hazard ratio would quantify statistical uncertainty around the estimated treatment effect under the model and sampling framework. A narrow interval would indicate greater precision than a wide interval, all else equal.
A p-value would quantify the compatibility of the observed data with a specified null hypothesis under the statistical testing framework. It would not measure the magnitude of the treatment effect, clinical importance, or probability that one treatment is beneficial.
A hazard ratio is a relative measure. Absolute event probabilities at clinically meaningful time points would provide a different perspective and would be particularly useful for understanding the practical magnitude of a treatment difference.
12. Statistical Issues in Composite Cardiovascular Outcomes
Component weighting
A standard composite analysis generally treats each qualifying component as sufficient to trigger the endpoint. This means that cardiovascular death, stroke, and myocardial infarction enter the composite according to the endpoint definition rather than receiving investigator-assigned numerical weights.
Clinical importance of components
The clinical importance of individual components can differ even when the statistical analysis combines them. For that reason, interpretation of a composite should distinguish the overall endpoint from its individual components whenever component-level results are available.
First-event versus recurrent-event analysis
The registered endpoint is presented as a composite event outcome. A conventional primary time-to-event analysis would generally focus on time to the first qualifying event. Recurrent-event methods answer a different question and should not be substituted without a prespecified rationale.
Competing risks
Death from one cause can prevent a participant from subsequently experiencing another event. Depending on the exact analytic estimand, competing-risk methods may be relevant for component-specific analyses. The ClinicalTrials.gov record does not specify a competing-risk methodology.
13. Treatment Duration and Follow-Up
The registry lists a duration of treatment of 5 years for both MK0954 and atenolol. This duration is an intervention characteristic rather than a statistical result.
| Intervention | Listed duration of treatment |
|---|---|
| MK0954 | 5 Years |
| Atenolol | 5 Years |
A five-year treatment duration creates a setting in which time-to-event methodology is particularly relevant because participants can experience cardiovascular events at different points during a prolonged observation period. The treatment duration itself, however, does not establish an outcome difference between the groups.
14. What the Registry Reports — and What It Does Not
The ClinicalTrials.gov record identifies the study design, population condition, interventions, enrollment, dates, and registered primary endpoint. It does not contain posted statistical analyses for the primary endpoint.
| Information category | Registry record |
|---|---|
| Trial status | Completed |
| Enrollment | 496 |
| Primary endpoint | Registered |
| Posted statistical analyses | None |
| Primary endpoint effect estimate | Not reported |
| Confidence interval | Not reported |
| P-value | Not reported |
| Arm-specific event counts | Not reported |
This distinction is important statistically. A completed trial does not necessarily mean that a statistical analysis is posted in the ClinicalTrials.gov results record. Trial completion describes study status; an effect estimate, confidence interval, and hypothesis test require an accompanying statistical analysis.
15. Limitations
- No posted statistical analyses: the ClinicalTrials.gov record does not report a treatment-effect estimate, confidence interval, p-value, or event count for the registered primary endpoint.
- Composite endpoint: the primary endpoint combines cardiovascular death, fatal and nonfatal stroke, and fatal and nonfatal myocardial infarction. A composite result would require careful consideration of its individual components.
- Unspecified statistical details: the registry information available here does not specify the exact primary analysis model, test procedure, stratification variables, missing-data strategy, or analysis-population definitions.
- Hazard-ratio assumptions: if a Cox proportional-hazards model were used, interpretation of a single hazard ratio would depend on the proportional-hazards assumption.
- Censoring: time-to-event analyses depend on appropriate handling and assumptions concerning censoring.
- Clinical interpretation: the overall composite endpoint and its individual components answer related but distinct clinical questions.
- Registry scope: the ClinicalTrials.gov record provides trial-registration information but does not contain posted statistical analyses for this study.
16. Why This Trial Matters Statistically
LIFE provides a useful teaching example of how a randomized prevention trial can be framed around a composite cardiovascular time-to-event endpoint. Even without posted numerical outcome analyses in the registry record, the design illustrates several fundamental principles of clinical-trial statistics.
| Concept | How it appears in LIFE |
|---|---|
| Randomization | The allocation is described as randomized. |
| Parallel design | The design model is parallel. |
| Double masking | The registry describes the study as double-masked. |
| Prevention | The primary purpose is prevention. |
| Composite endpoint | Cardiovascular death, fatal and nonfatal stroke, and fatal and nonfatal myocardial infarction form the registered primary endpoint. |
| Time-to-event analysis | A composite cardiovascular endpoint observed over prolonged treatment is naturally suited to survival-analysis methods. |
| Hazard ratio | A conventional Cox analysis would express the relative event rate between randomized groups as a hazard ratio. |
| Kaplan-Meier estimation | A conventional analysis could estimate event-free survival over time. |
| Log-rank testing | A conventional randomized-group comparison could use a log-rank test for time-to-event distributions. |
| Component interpretation | The composite must be distinguished from the individual cardiovascular death, stroke, and myocardial infarction components. |
17. Statistical Concepts in This Trial
The LIFE design connects directly to several core concepts in clinical-trial statistics: randomized comparisons, composite endpoints, survival functions, censoring, hazard ratios, Kaplan-Meier estimation, and Cox proportional-hazards modeling.
Randomized comparison
Random allocation provides the principal design framework for comparing the two interventions.
Composite outcome
The primary endpoint combines cardiovascular death, stroke, and myocardial infarction.
Time-to-event analysis
The timing of cardiovascular events can be incorporated rather than reducing follow-up to a simple yes/no outcome.
Hazard ratio
A Cox model can express the relative instantaneous event rate between treatment groups.
18. Planned Statistical Framework in Practice
For an endpoint of this type, a complete statistical analysis would normally begin by defining the estimand: the population, treatment comparison, endpoint definition, handling of intercurrent events, and summary measure. The analysis would then establish the event and censoring rules before comparing the randomized groups.
| Step | Statistical purpose |
|---|---|
| 1. Define the endpoint | Identify cardiovascular death, fatal and nonfatal stroke, and fatal and nonfatal myocardial infarction as the qualifying components. |
| 2. Establish event time | Determine the relevant time from randomization to the qualifying endpoint. |
| 3. Define censoring | Specify when a participant who has not experienced the endpoint is censored. |
| 4. Estimate event-free survival | Use a Kaplan-Meier approach to describe the time-to-event distribution. |
| 5. Compare randomized groups | Use an appropriate survival-analysis hypothesis test, commonly a log-rank test. |
| 6. Estimate relative effect | Use a Cox proportional-hazards model to estimate a hazard ratio when its assumptions are appropriate. |
| 7. Quantify uncertainty | Report a confidence interval around the treatment-effect estimate. |
| 8. Examine components | Describe the individual composite components separately when component-level data are available. |
This framework explains how a statistical analysis of the registered endpoint would ordinarily be structured without treating a generic method as though it were a documented analysis from the registry.
19. Statistical Interpretation of a Future Effect Estimate
A hazard ratio below 1 would indicate a lower estimated instantaneous rate of the composite endpoint in the MK0954 group relative to the atenolol group, under the fitted model. It would not mean that the same percentage reduction occurred in every participant or that the relative effect was identical for cardiovascular death, stroke, and myocardial infarction.
A hazard ratio above 1 would indicate a higher estimated instantaneous rate of the composite endpoint in the MK0954 group relative to the atenolol group, under the fitted model. It would still be necessary to examine the confidence interval and absolute event probabilities before interpreting the magnitude and precision of the difference.
For a hazard ratio, the conventional null value is 1. A confidence interval containing 1 would indicate that the data are compatible with no relative hazard difference under the specified confidence framework. That statement concerns statistical uncertainty, not proof that the treatments are identical.
A p-value addresses evidence against a specified null hypothesis. It does not tell the reader how large the treatment difference is. The hazard ratio, its confidence interval, and absolute event probabilities provide the information needed to understand magnitude and precision.
20. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The randomized design establishes a framework for comparing time to the registered composite cardiovascular endpoint. A conventional analysis would quantify both relative and absolute differences while accounting for censoring and event timing.
Clinical interpretation
The primary endpoint concerns major cardiovascular outcomes: cardiovascular death, fatal and nonfatal stroke, and fatal and nonfatal myocardial infarction. Its clinical interpretation depends on the overall composite as well as the individual components.
The distinction is important because a statistically estimated difference in a composite endpoint is not automatically equivalent to a uniform difference in every component. A rigorous interpretation should keep the statistical estimand and the clinical meaning of the endpoint aligned.
21. Questions a Statistical Analysis Should Answer
What is being compared? MK0954 versus atenolol.
Who is being compared? Participants assigned through the randomized trial design.
What is the endpoint? The registered composite of cardiovascular death, fatal and nonfatal stroke, and fatal and nonfatal myocardial infarction.
What is the time scale? Time from randomization to the qualifying cardiovascular endpoint under a conventional time-to-event framework.
What is the effect measure? A hazard ratio is a conventional relative measure for this type of endpoint.
What establishes precision? A confidence interval around the estimated treatment effect.
22. Limitations of Interpreting Registry-Only Results
The ClinicalTrials.gov record establishes the registered design and endpoint but does not provide a posted statistical analysis for the primary outcome. Consequently, the registry record alone does not provide the numerical evidence required to describe an observed treatment effect.
This is an important distinction for clinical-trial readers. Study registration answers questions such as what was studied, how participants were allocated, which interventions were evaluated, and what endpoint was registered. Statistical results require a separate analysis record containing the observed event data and corresponding statistical estimates.
23. Sources
- ClinicalTrials.gov: LIFE — NCT00338260.
Continue through the Clinical Biostats clinical-trial resources
Explore additional clinical-trial analyses and statistical resources for understanding randomized study design, endpoints, and quantitative interpretation.
24. Record Summary
LIFE is a phase 3 randomized, parallel, double-masked prevention trial with 496 participants, evaluating MK0954, identified as losartan in the study title, against atenolol. Both interventions have a listed treatment duration of 5 years. The registered primary endpoint is a composite of cardiovascular death, fatal and nonfatal stroke, and fatal and nonfatal myocardial infarction.
From a statistical perspective, the trial is a useful example of a randomized time-to-event comparison built around a clinically important composite outcome. The appropriate analytical framework would ordinarily combine treatment-group comparison with Kaplan-Meier estimation, an appropriate hypothesis test such as the log-rank test, and a relative treatment-effect measure such as a Cox-model hazard ratio, together with confidence intervals and careful interpretation of the individual composite components.